These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 27168431)

  • 41. Congress works to permit 'biosimilar' drugs very soon.
    Carroll J
    Manag Care; 2009 Apr; 18(4):7-8. PubMed ID: 19472559
    [No Abstract]   [Full Text] [Related]  

  • 42. The impact of generic substitution on price competition in Finland.
    Aalto-Setälä V
    Eur J Health Econ; 2008 May; 9(2):185-91. PubMed ID: 17508226
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prozac. A bitter pill.
    McLean B
    Fortune; 2001 Aug; 144(3):118-22, 126, 130-2. PubMed ID: 11499050
    [No Abstract]   [Full Text] [Related]  

  • 44. Who's really raising drug prices?
    Zagorin A
    Time; 1999 Mar; 153(9):46-8. PubMed ID: 10346086
    [No Abstract]   [Full Text] [Related]  

  • 45. Why are we Being Overcharged for Pharmaceuticals? What Should We Do About It?
    Hyman DA; Silver C
    J Leg Med; 2019; 39(2):137-149. PubMed ID: 31503533
    [No Abstract]   [Full Text] [Related]  

  • 46. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
    Apel BT
    Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
    [TBL] [Abstract][Full Text] [Related]  

  • 47. India: access to affordable drugs and the right to health.
    Grover A; Citro B
    Lancet; 2011 Mar; 377(9770):976-7. PubMed ID: 21227487
    [No Abstract]   [Full Text] [Related]  

  • 48. Addressing Generic-Drug Market Failures - The Case for Establishing a Nonprofit Manufacturer.
    Liljenquist D; Bai G; Anderson GF
    N Engl J Med; 2018 May; 378(20):1857-1859. PubMed ID: 29768140
    [No Abstract]   [Full Text] [Related]  

  • 49. Generic medicine pricing in Europe: current issues and future perspective.
    Simoens S
    J Med Econ; 2008; 11(1):171-5. PubMed ID: 19450118
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Competition and the Reference Pricing Scheme for pharmaceuticals.
    Ghislandi S
    J Health Econ; 2011 Dec; 30(6):1137-49. PubMed ID: 21937137
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SaskPharm: a proposal for provincial drug production.
    Meili R
    CMAJ; 2011 Jul; 183(10):1224. PubMed ID: 21609991
    [No Abstract]   [Full Text] [Related]  

  • 52. Selling Patents to Indian Tribes to Delay the Market Entry of Generic Drugs.
    Ablavsky G; Larrimore Ouellette L
    JAMA Intern Med; 2018 Feb; 178(2):179-180. PubMed ID: 29297039
    [No Abstract]   [Full Text] [Related]  

  • 53. [Generic medicines].
    Peláez de Loño J
    Rev Enferm; 1999 Dec; 22(12):836-43. PubMed ID: 10797771
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
    Graul AI; Revel L; Rosa E; Cruces E
    Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The ethics and economics of pharmaceutical pricing.
    Parker-Lue S; Santoro M; Koski G
    Annu Rev Pharmacol Toxicol; 2015; 55():191-206. PubMed ID: 25149920
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Product-line extensions and pricing strategies of brand-name drugs facing patent expiration.
    Hong SH; Shepherd MD; Scoones D; Wan TT
    J Manag Care Pharm; 2005; 11(9):746-54. PubMed ID: 16300418
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Hatch-Waxman Act: balancing competing interests or survival of the fittest?
    Behrendt KE
    Food Drug Law J; 2002; 57(2):247-71. PubMed ID: 12436990
    [No Abstract]   [Full Text] [Related]  

  • 58. The $2.6 billion pill--methodologic and policy considerations.
    Avorn J
    N Engl J Med; 2015 May; 372(20):1877-9. PubMed ID: 25970049
    [No Abstract]   [Full Text] [Related]  

  • 59. Prescription drug pricing: do competitive forces operate in the pharmaceutical marketplace?
    Margolis RE
    Healthspan; 1994 Feb; 11(2):9-16. PubMed ID: 10132991
    [No Abstract]   [Full Text] [Related]  

  • 60. [Blocking of generic drugs must be fought].
    Kringlen E
    Tidsskr Nor Laegeforen; 2013 Oct; 133(19):2032. PubMed ID: 24129531
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.